TherapeuticsMD, Inc. (TXMD) Q1 2022 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Therapeuticsmd, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.009 -- 00:00:03.670 Good afternoon, ladies and gentlemen. Thank you for joining us for TherapeuticsMD's first 00:00:03.670 -- 00:00:07.291 quarter 2022 financial results conference call. 00:00:07.291 -- 00:00:12.232 I will now turn the call over to Investor Relations for TherapeuticMD's Lisa Wilson. 00:00:12.232 -- 00:00:14.492 You may begin. 00:00:22.134 -- 00:00:25.259 Thank you, Operator. Good afternoon, everyone. 00:00:25.259 -- 00:00:30.101 and thank you for joining today to discuss our first quarter financial results and business 00:00:30.101 -- 00:00:34.382 update. This afternoon, TherapeuticsMD 00:00:34.382 -- 00:00:38.823 issued a press release announcing its first quarter 2022 00:00:38.823 -- 00:00:40.844 financial results. 00:00:40.844 -- 00:00:46.726 The press release and accompanying presentation are available on the company's website, 00:00:46.726 -- 00:00:48.306 TherapeuticsMD, 00:00:48.306 -- 00:00:52.285 in the Investors and Media section. 00:00:52.285 -- 00:00:57.507 On today's call from TherapeuticsMD are Chief Executive Officer Hugh 00:00:57.507 -- 00:00:58.968 O'Dowd, 00:00:58.968 -- 00:01:02.990 Interim Chief Financial Officer Michael Donegan, 00:01:02.990 -- 00:01:06.871 and Chief Commercial Officer Mark Glickman. 00:01:06.871 -- 00:01:11.833 I would like to remind everyone that certain statements made during this conference call 00:01:11.833 -- 00:01:14.514 may be forward-looking statements. 00:01:14.514 -- 00:01:19.332 Such forward-looking statements are based upon current expectations and there can be 00:01:19.332 -- 00:01:25.595 no assurance that the results contemplated in these statements will be realized. 00:01:25.595 -- 00:01:30.937 Actual results may differ materially from such statements due to a number of factors 00:0...